Arabesque Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Arabesque Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,199	Closed	-$3.75M	–	104
2022 Q4	$3.75M	Buy	5,199 +1,390	+36%	+$1.03M	1.27%	21
2022 Q3	$2.62M	Buy	3,809 +474	+14%	+$298K	1.28%	11
2022 Q2	$1.97M	Buy	3,335 +388	+13%	+$252K	1.04%	42
2022 Q1	$2.06M	Buy	+2,947	New	+$1.86M	0.71%	71
2021 Q4	–	Sell	-3,306	Closed	-$2M	–	200
2021 Q3	$2M	Buy	+3,306	New	+$2.05M	0.67%	68
2020 Q3	–	Sell	-5,102	Closed	-$3.18M	–	90
2020 Q2	$3.18M	Buy	+5,102	New	+$2.9M	2.16%	16

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Arabesque Asset Management's REGN Position: Q1 2023 in Review

Arabesque Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 5,199 shares — an estimated $3.75M sold.

Arabesque Asset Management first reported a position in REGN in Q2 2020 and held it in 6 quarters. The position peaked at $3.75M in Q4 2022. 1,191 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

Arabesque Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Arabesque Asset Management sold 5,199 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $3.75M.
Arabesque Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 6 quarters.
Arabesque Asset Management's Regeneron Pharmaceuticals position peaked at $3.75M in Q4 2022.
1,191 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on Arabesque Asset Management's 13F filing for Q1 2023.